Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3306-3312

  Longo, Olimpia ^a   Tripiciano, Antonella ^a   Fiorelli, Valeria ^a   Bellino, Stefania ^a   Scoglio, Arianna ^a   Collacchi, Barbara ^a   Alvarez, Maria Josè Ruiz ^a   Francavilla, Vittorio ^b   Arancio, Angela ^b   Paniccia, Giovanni ^b   Lazzarin, Adriano ^c   Tambussi, Giuseppe ^c   Din, Chiara Tassan ^c   Visintini, Raffaele ^c   Narciso, Pasquale ^d   Antinori, Andrea ^d   D'Offizi, Gianpiero ^d   Giulianelli, Marina ^d   Carta, Maria ^e   Di Carlo, Aldo ^b   Palamara, Guido ^b   Giuliani, Massimo ^b   Laguardia, Maria Elena ^f   Monini, Paolo ^a   Magnani, Mauro ^f   Ensoli, Fabrizio ^b   Ensoli, Barbara ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF URBINO   (Italy)

Author keywords

Clinical trial; HIV; Vaccination

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIBODY; PLACEBO; TAT ANTIBODY; TAT PROTEIN VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BLOOD DISEASE; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EAR DISEASE; FOLLOW UP; GASTROINTESTINAL DISEASE; HELPER CELL; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INFESTATION; INJECTION SITE REACTION; INNER EAR DISEASE; LONG TERM CARE; LYMPHATIC SYSTEM DISEASE; MENTAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; TH2 CELL; VACCINATION;

AIDS VACCINES; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; VIRAL LOAD;

EID: 67349268940     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.090     Document Type: Article

References (24)

1. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engström G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71 7 (1997) 5528-5539
2. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2 9 (1996) 960-964
3. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 1 (1993) 277-287
4. Arya S.K., Guo C., Josephs S.F., and Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229 4708 (1985) 69-73
5. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320 6060 (1986) 367-371
6. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168 1 (2002) 197-206
7. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 20-22 (2001) 2862-2877
8. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothé B.R., Vogel T.U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407 6802 (2000) 386-390
9. Cao J., McNevin J., Holte S., Fink L., Corey L., and McElrath M.J. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77 12 (2003) 6867-6878
10. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22 25-26 (2004) 3258-3269
11. Reiss P., Lange J.M., de Ronde A., de Wolf F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 30 3 (1990) 163-168
12. Richardson M.W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57 1 (2003) 4-14
13. Van Baalen C.A., Schutten M., Huisman R.C., Boers P.H., Gruters R.A., and Osterhaus A.D. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 72 August (8) (1998) 6851-6857
14. Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Tat Multicentric Study Group. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 188 8 (2003) 1171-1180
15. Opi S., Péloponèse Jr. J.M., Esquieu D., Campbell G., de Mareuil J., Walburger A., et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem 277 39 (2002) 35915-35919
16. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Buttò S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 20 18 (2006) 2245-2261
17. Doutre M.S., Beylot C., Beylot J., Long P., Royer P., and Lacoste D. Peripheral facial paralysis and HIV infection. 2. Case reports. Rev Med Interne 13 5 (1992) 354-358
18. Chang H.K., Gallo R.C., and Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J Biomed Sci 2 August (3) (1995) 189-202
19. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 98 4 (2001) 1781-1786
20. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De Rosa V., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 10 4 (1995) 408-416
21. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21 1 (2001) 81-89
22. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1 4 (1998) 282-292
23. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS. 22 16 (2008) 2207-2209
24. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., and Tripiciano A. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 191 8 (2005) 1321-1324 Epub 2005 Mar 14